PharmFilm technology to be used for pediatric applications
Drug firm Lupin and US-based specialty pharmaceutical firm MonoSol Rx have signed a licensing agreement for multiple pediatric products.
“Lupin Pharma, the company’s US subsidiary, and MonoSol Rx have entered into a licensing agreement wherein Lupin would develop multiple pediatric products utilising MonoSol Rxs PharmFilm drug delivery technology,”Lupin said in a BSE filing.
The agreement would be in line with focus on expanding into the specialty pharma market and specifically pediatric needs such as attention-deficit/ hyperactivity disorder (ADHD), Lupin said. “We believe PharmFilm technology holds great promise for pediatric applications enabling increased compliance and adherence in a difficult to treat population,” MonoSol Rx CEO Keith J Kendall said.